Dr. Pieczonka on initial efficacy and safety data for sabizabulin (VERU-111) in mCRPC

Video

Christopher Pieczonka, MD, director of clinical research, Crouse Health, discusses phase 2 data for the novel oral cytoskeletal disruptor sabizabulin (VERU-111) in metastatic castration-resistant prostate cancer (mCRPC) presented during the 2021 ASCO Annual Meeting (J Clin Oncol 39, 2021 [suppl 15; abstr 5056]. doi:10.1200/JCO.2021.39.15_suppl.5056). He also discusses toxicity differences between VERU-111 and docetaxel.

According to Pieczonka, additional phase 2 data for VERU-111 will be shared in September at the upcoming 2021 ESMO Annual Meeting. A phase 3 trial (NCT04844749) of VERU-111 in mCRPC has already been launched.

Related Videos
Dr. Jasmeet Kaur in an interview with Urology Times
Dr. Martin Voss in an interview with Urology Times
Dr. Jacqueline Brown in an interview with Urology Times
blurred clinic hallway
Dr. Dalia Kaakour in an interview with red Urology Times backdrop
Dr. Maria Teresa Bourlon in an interview with Urology Times
Dr. David Braun in an interview with Urology Times
Dr. Neeraj Agarwal in an interview with Urology Times
Dr. Saby George in an interview with Urology Times
Dr. Laura Bukavina in an interview with Urology Times
Related Content
© 2024 MJH Life Sciences

All rights reserved.